Vaccinex, Inc. Files 8-K Report
Ticker: VCNX · Form: 8-K · Filed: Mar 28, 2024 · CIK: 1205922
| Field | Detail |
|---|---|
| Company | Vaccinex, Inc. (VCNX) |
| Form Type | 8-K |
| Filed Date | Mar 28, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $7.77, $1.5 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, financials
TL;DR
VACCINEX filed an 8-K, likely with financial updates. Keep an eye out.
AI Summary
On March 28, 2024, Vaccinex, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant occurrences. No specific monetary amounts or new events were detailed in the provided excerpt.
Why It Matters
This filing signals that Vaccinex, Inc. is providing updated information to the SEC, which could include material events or financial disclosures relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report, which typically contains routine disclosures rather than immediate, high-impact news.
Key Players & Entities
- Vaccinex, Inc. (company) — Registrant
- 001-38624 (company) — Commission File Number
- 16-1603202 (company) — IRS Employer Identification No.
- 1895 Mount Hope Avenue (company) — Principal executive offices address
- Rochester (company) — City of principal executive offices
- New York (company) — State of principal executive offices
- 14620 (company) — Zip code of principal executive offices
- (585) 271-2700 (company) — Registrant's telephone number
FAQ
What specific "Other Events" are being reported by Vaccinex, Inc. in this 8-K filing?
The provided excerpt does not detail the specific "Other Events" being reported; it only lists the item category.
What "Financial Statements and Exhibits" are included with this 8-K filing?
The excerpt states that "Financial Statements and Exhibits" are part of the filing but does not list their specific contents.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on March 28, 2024.
What is Vaccinex, Inc.'s principal executive office address?
Vaccinex, Inc.'s principal executive office is located at 1895 Mount Hope Avenue, Rochester, New York 14620.
What is Vaccinex, Inc.'s telephone number?
Vaccinex, Inc.'s telephone number, including area code, is (585) 271-2700.
Filing Stats: 507 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-03-28 16:54:35
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share VCNX Nasdaq Capital Marke
- $7.77 — of Common Stock at a combined price of $7.77 per Share and Common Warrant (the "Offe
- $1.5 million — gregate gross proceeds of approximately $1.5 million. The Offering was previously disclosed
Filing Documents
- d798997d8k.htm (8-K) — 25KB
- d798997dex51.htm (EX-5.1) — 8KB
- g798997g0328234954870.jpg (GRAPHIC) — 2KB
- 0001193125-24-080804.txt ( ) — 155KB
- vcnx-20240328.xsd (EX-101.SCH) — 3KB
- vcnx-20240328_lab.xml (EX-101.LAB) — 17KB
- vcnx-20240328_pre.xml (EX-101.PRE) — 11KB
- d798997d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Exhibit Description 5.1 Opinion of Hogan Lovells US LLP. 23.1 Consent of Hogan Lovells US LLP (included in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. Vaccinex, Inc. Date: March 28, 2024 By: /s/ Maurice Zauderer Maurice Zauderer Chief Executive Officer